Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-15T01:22:06.116Z Has data issue: false hasContentIssue false
  • English
  • Français

Harmonizing Standards and Incentives in Medical Device Regulation: Lessons Learned from the Parallel Review Pathway

Published online by Cambridge University Press:  01 January 2021

Jessica N. Holtzman  and
Daniel B. Kramer
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Health Policy Portal
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue 4: Next Steps in Health Reform , Winter 2018 , pp. 1034 - 1039
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Medicare and Medicaid Services & Food and Drug Administration. Parallel review of medical products, available at <https://www.federalregister.gov/documents/2010/09/17/2010-23252/parallel-review-of-medical-products> (last accessed November 27, 2018.+(last+accessed+November+27,+2018.>Google Scholar
Kramer, D.B., Xu, S., and Kesselheim, A.S., “Regulation of Medical Devices in the United States and European Union,” New England Journal of Medicine 366, no. 9 (2012): 848–855.Google Scholar
US Food and Drug Administration, Premarket Application Review Process, available at <https://www.fda.gov/MedicalDevices/DeviceRegulationand-Guidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm047991.htm> (last accessed November 27, 2018).+(last+accessed+November+27,+2018).>Google Scholar
U.S. FDA. Code of Federal Regulations. Title 21, Volume 8, Chapter I, Subchapter H, Part 860, available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?FR=860.7> (last visited November 27, 2018).+(last+visited+November+27,+2018).>Google Scholar
Dhruva, S.S., Bero, L.A., and Redberg, R.F., “Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices,” JAMA 302, no. 24 (2009): 2679–2685; V.K. Rathi, H.M. Krumholz, and F.A. Masoudi, J.S. Ross, “Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011,” JAMA 314, no. 6 (2015):604-612.Google Scholar
Chambers, J.D., May, K.E., and Neumann, P.J., “Medicare Covers the Majority of FDA-Approved Devices and Part B Drugs, but Restrictions and Discrepancies Remain,” Health Affairs (Mill-wood) 32, no. 6 (2013):1109–1115.Google Scholar
Tunis, S., Berenson, R., Phurrough, S., and Mohr, P., “Improving the Quality and Efficiency of the Medicare Program through Coverage Policy Issues,” Urban Institute (2011), available at <http://www.urban.org/sites/default/files/alfresco/publication-pdfs/412392-Improving-the-Quality-and-Efficiency-of-the-Medicare-Program-Through-Coverage-Policy.PDF> (last accessed November 27, 2018); P.J. Neumann and J.D. Chambers, “Medicare's Enduring Struggle to Define ‘Reasonable and Necessary’ Care, New England Journal of Medicine 367, no. 19 (2012): 1775-1777.+(last+accessed+November+27,+2018);+P.J.+Neumann+and+J.D.+Chambers,+“Medicare's+Enduring+Struggle+to+Define+‘Reasonable+and+Necessary’+Care,+New+England+Journal+of+Medicine+367,+no.+19+(2012):+1775-1777.>Google Scholar
Centers for Medicare and Medicaid Services. Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4), available at <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=263> (last accessed November 27, 2018).+(last+accessed+November+27,+2018).>Google Scholar
Department of Health and Human Services, “Local Coverage Determinations Create Inconsistency in Medicare Coverage,” available at <https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf> (last accessed November 27, 2018).+(last+accessed+November+27,+2018).>Google Scholar
114th Congress. Public Law 114-255. 21st Century Cures Act. (last accessed August 30, 2018).Google Scholar
Neumann, P.J., Kamae, M.S., and Palmer, J.A., “Medicare's National Coverage Decisions for Technologies, 1999-2007, Health Affairs (Millwood) 27, no. 6 (2008):1620–1631.Google ScholarPubMed
Center for Medicaid and Medicare Services. Coverage with evidence development, available at <https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/> (last accessed November 27, 2018); see Tunis, supra note 7.+(last+accessed+November+27,+2018);+see+Tunis,+supra+note+7.>Google Scholar
Centers for Medicare and Medicaid Services, Guidance for the Public, Industry, and CMS Staff: Coverage with Evidence Development, available at <https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=27> (last accessed November 27, 2018).+(last+accessed+November+27,+2018).>Google Scholar
Krucoff, M.W., Brindis, R.G., Hodgson, P.K., Mack, Mj.J., and Holmes, Jr., “Medical Device Innovation: Prospective Solutions for an Ecosystem in Crisis. Adding a Professional Society Perspective,” JACC: Cardiovascular Interventions 5, no. 7 (2012):790–796; Lindor, R.A., Allocco, S.J., Cheatham, L., et al. “Regulatory and Reimbursement Innovation,” Science Translational Medicine 5, no. 176 (2013):176cm3.Google Scholar
Messner, D.R. and Tunis, S.R., “Current and Future State of FDA-CMS Parallel Reviews, Clinical Pharmacology & Therapeutics 91, no. 3 (2012): 383–385.Google Scholar
Ridge, J.R. and Statz, S., “Exact Sciences’ Experience with the FDA and CMS Parallel Review Program,” Expert Review of Molecular Diagnostics 15, no. 9 (2015):1117–1124.CrossRefGoogle Scholar
Centers for Medicare and Medicaid Services, Medicare Program Integrity Manual – Chapter 13 Local Coverage Determinations, available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/…/pim83c13.pdf> (last accessed November 27, 2018).+(last+accessed+November+27,+2018).>Google Scholar
Memorandum of Understanding between United States Food and Drug Administration and Centers for Medicare & Medicaid Services In: Administration FaD, ed.2010.Google Scholar
Pilot Program for Parallel Review of Medical Products In: Administration CfMaMSFaD, ed.2011:62808-10; Services DoHaH. Medicare Program: Revised Process for Making National Coverage Determinations. In: Services CfMM, ed. Federal Register2003:55634-41.Google Scholar
Chambers, supra note 6; Basu, S. and Hassenplug, J.C., “Patient Access to Medical Devices — A Comparison of U.S. and European Review Processes,” New England Journal of Medicine 367, no. 6 (2012):485–488.CrossRefGoogle Scholar
Chambers, J.D., Chenoweth, M., Thorat, T., and Neumann, P.J., “Private Payers Disagree with Medicare over Medical Device Coverage about Half the Time,” Health Affairs (Millwood) 34, no. 8 (2015):1376–1382.Google Scholar
Forman, D.E., Maurer, M.S., Boyd, C., et al., “Multimorbidity in Older Adults With Cardiovascular Disease,” Journal of the American College of Cardiology 71, no. 19 (2018): 2149–2161.Google Scholar
Dhruva, S.S., Mazure, C.M., Ross, J.S., Redberg, R.F., “Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices,” JAMA Internal Medicine 177, no. 9 (2017):1390–1391.CrossRefGoogle Scholar
National Academies of Sciences, Engineering, and Medicine, “Strategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials,” (Washington, DC: National Academies Press, August 24, 2016), available at <https://www.ncbi.nlm.nih.gov/pubmed/27606381> (last accessed November 27, 2018); US Food and Drug Administration, “FDA Report: Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products,” August 2013, available at <https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/UCM365544.pdf> (last accessed November 27, 2018).+(last+accessed+November+27,+2018);+US+Food+and+Drug+Administration,+“FDA+Report:+Collection,+Analysis,+and+Availability+of+Demographic+Subgroup+Data+for+FDA-Approved+Medical+Products,”+August+2013,+available+at++(last+accessed+November+27,+2018).>Google Scholar
Richardson, E., “Health Policy Brief: Aligning FDA and CMS Review,” Health Affairs (2015), available at <https://www.healthaffairs.org/do/10.1377/hpb20150827.132391/full/> (last accessed December 12, 2018); F. Zannad, M.L.A. Alonso Garcia, and J.S. Borer, et al. “Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement,” Journal of the American College of Cardiology 70, no. 22 (2017):2822-2830.Google Scholar
Rickard, J., Michtalik, H., Sharma, R., et al., “Use of Cardiac Resynchronization Therapy in the Medicare Population,” AHRQ Technology Assessment, Rockville, MD, 2015.Google Scholar
Kramer, D.B. and Steinhaus, D.A., “Cardiac Resynchronization Therapy in Older Patients: Age Is Just a Number, and Yet…,” Journal of Cardiac Failure 22, no. 12 (2016): 978–980; Elming, M.B., Nielsen, J.C., Haarbo, J., et al., “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure,” Circulation 136, no. 19 (2017):1772-1780.Google Scholar
US Food and Drug Administration, Medical Devices: Databases, 510(k) premarket notification, available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> (last acessed November 27, 2018).+(last+acessed+November+27,+2018).>Google Scholar
Institute of Medicine, Medical Devices and the Public's Health: The FDA 510(k) Clearance Process at 35 Years, Washington, DC: National Academies Press, 2011; Ardaugh, B.M., Graves, S.E., and Redberg, R.F., “The 510(k) Ancestry of a Metal-on-Metal Hip Implant,” New England Journal of Medicine 368, no. 2 (2013): 97-100.Google Scholar
See Chambers, supra note 6.Google Scholar
Forman, supra note 22.Google Scholar
Dhruva, S.S. and Redberg, R.F., “Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence used for Medicare National Coverage Decisions,” Archives of Internal Medicine 168, no. 2 (2008):136–140.Google Scholar
Tisminetzky, M., Bayliss, E.A., Magaziner, J.S., et al., “Research Priorities to Advance the Health and Health Care of Older Adults with Multiple Chronic Conditions,” Journal of the American Geriatrics Society 65, no. 7 (2017):1549–1553; A.S. Bierman and M.E. Tinetti, “Precision Medicine to Precision Care: Managing Multimorbidity, Lancet 388, no. 10061 (issue number?)(2016): 2721-2723.Google Scholar
Department of Health and Human Services, Office of Inspector General, Local Coverage Determinations Create Inconsistency in Medicare Coverage, OEI-01-11-00500, January 2014.Google Scholar
Centers for Medicare and Medicaid Services, Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4), available at <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=263> (last acessed November 27, 2018).+(last+acessed+November+27,+2018).>Google Scholar
Centers for Medicare and Medicaid Services, Decision Memo for Transcatheter Aortic Valve Replacement (CAG-00430N), available at <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=257&ver=4&NcaName=Transcatheter+Aortic+Valve+Replacement+(TAVR)&bc=ACAAAAAAIAAA&> (last acessed November 27, 2018).+(last+acessed+November+27,+2018).>Google Scholar